Article
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
The oncologist - 1 Jul 2016
Hertz Daniel L, Deal Allison, Ibrahim Joseph G, Walko Christine M, Weck Karen E, Anderson Steven, Magrinat Gustav, Olajide Oludamilola, Moore Susan, Raab Rachel, Carrizosa Daniel R, Corso Steven, Schwartz Garry, Graham Mark, Peppercorn Jeffrey M, Jones David R, Desta Zeruesenay, Flockhart David A, Evans James P, McLeod Howard L, Carey Lisa A, Irvin William J
Abstract excerpt
BACKGROUND: Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We previously reported that by increasing the daily tamoxifen dose to 40 mg/day in CYP2D6 intermediate metabolizer (IM), but not poor metabolizer (PM), patients achieve endoxifen concentrations similar to those of extensive metabolizer patients on 20 mg/day. We expanded enrollment to assess the safety of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.